1. Introduction {#sec1}
===============

For over 50 years endurance exercise has been known to induce mitochondrial adaptations in skeletal muscle [@bib1], [@bib2], [@bib3], [@bib4]. While the mechanisms by which contraction initiates mitochondrial biogenesis remain to be fully elucidated, it is clear that perturbation in allosteric factors such as calcium (Ca^2+^)^1^, adenosine monophosphate (AMP), nicotinamide-adenine dinucleotide (NAD^+^), and acetyl-CoA are important initiators of the adaptive response [@bib5], [@bib6], [@bib7], [@bib8]. Accordingly, considerable research has focused on the transduction pathways that are modulated by these metabolic intermediates and their contribution to exercise-induced mitochondrial adaptations in skeletal muscle. Reversible lysine acetylation has emerged as an important posttranslational modification that links cellular flux to the adaptive responses [@bib9], [@bib10]. An underlying reason for this is that NAD^+^ is the primary substrate for the sirtuin class of deacetylases (DACs), which remove acetyl groups from lysine residues [@bib11], whilst acetyl-CoA is the substrate for acetyltransferases (KATs), which add acetyl groups to lysine residues [@bib12]. However, despite the high prevalence of lysine acetylation in skeletal muscle [@bib13], [@bib14] much remains unknown regarding its contribution to the remodeling of skeletal muscle, both at rest and also in response to endurance exercise [@bib15].

Peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) is an important contributor to mitochondrial biogenesis and function in skeletal muscle [@bib2], [@bib5], [@bib6], with its transcriptional activity being regulated, at least in part, by reversible acetylation [@bib16], [@bib17], [@bib18]. Deacetylation by sirtuin 1 (SIRT1) is a potent activator of PGC-1α [@bib16], [@bib17], [@bib19], [@bib20], while general control of amino acid synthesis 5 (GCN5) acetylates and inhibits its transcriptional activity [@bib8], [@bib17], [@bib18], [@bib21]. GCN5 and PGC-1*α* form a complex in PGC-1*α* immunoprecipitates from Fao hepatocytes, while GCN5 overexpression in HEK293 cells represses PGC-1*α* intrinsic transcriptional activity [@bib18]. In relation to skeletal muscle, overexpression of GCN5 in C2C12 myotubes represses PGC-1*α*-mediated induction of mitochondrial and fatty acid metabolism genes [@bib17]. Moreover, we previously reported that deacetylation of PGC-1α following acute endurance exercise occurs in conjunction with a reduction in both the nuclear presence of GCN5 and its association with PGC-1*α* [@bib8]. This relationship was maintained in both the presence and absence of SIRT1 deacetylase activity, suggesting that exercise-induced deacetylation of PGC-1α occurs as a result of reduced GCN5-PGC-1*α* interaction, rather than solely through SIRT1-dependent deacetylation of PGC-1α [@bib8].

Taken together, these data implicate GCN5 as an important negative regulator of PGC-1α transcriptional activity in skeletal muscle and, by extension, mitochondrial biogenesis [@bib8], [@bib17], [@bib18], [@bib21]. However, no studies to date have directly investigated the contribution of GCN5 to skeletal muscle metabolism and mitochondrial function *in vivo*. Accordingly, we used CreLoxP methodology to generate mice with muscle-specific knockout of GCN5 (mKO). We hypothesized that mKO mice would display increased mitochondrial biogenesis in skeletal muscle as compared to their floxed/wildtype (WT) littermates and that mitochondrial adaptations to endurance exercise training (ExT) would be enhanced in mKO mice.

2. Materials and methods {#sec2}
========================

2.1. Generation of mKO mouse {#sec2.1}
----------------------------

To generate mKO mice, mice harboring LoxP sites flanking exons 3--19 of the GCN5 gene ([Figure 1](#fig1){ref-type="fig"}A) [@bib22] (referred to as GCN5^flox/flox^, and kindly provided by Dr. Sharon Dent, The University of Texas MD Anderson Cancer Center, Smithville TX, USA) were crossed with mice expressing Cre recombinase under the control of the muscle creatine kinase promoter (Cre-MCK); after Cre-mediated recombination, exons 3--19 are removed [@bib22]. Our breeding strategy was to breed GCN5^flox/flox^ mice with GCN5^flox/+^ ('+' refers to a WT allele) mice, with one breeder being Cre-MCK positive, and the other Cre-MCK negative. This provided littermates that were Cre-MCK positive or negative and GCN5^flox/flox^ or GCN5^flox/+^; mice that were GCN5^flox/+^ and Cre-MCK positive are heterozygous for loss of GCN5, and are referred to as mHZ. Mice negative for Cre-MCK are referred to as wildtype (WT) and were used as controls for all experiments. Mice were housed on a 12:12 h light--dark cycle, and all experiments were conducted in 13-wk-old littermates. All experiments were approved by and conducted in accordance with the Animal Care Program at the University of California, San Diego.Figure 1**Efficient gene deletion in skeletal muscle of GCN5 (mKO).** A) Schematic of LoxP sites flanking exons 3--19 of the GCN5 gene. B) GCN5 gene expression is diminished in mHZ and mKO compared to WT mice. C) Quantitation of GCN5 protein abundance in skeletal muscle of WT, mHZ, and mKO mice. D) Representative image of GCN5 protein abundance from whole-cell muscle lysates in WT, mHZ and mKO mice. D) GCN5 acetyltransferase activity is reduced in mKO compared to WT mice. E) Quantitation and F) representative images of protein abundance of PCAF, CBP, SIRT1, and SIRT3 in skeletal muscle from WT, mHZ and mKO mice. G) Quantitation and H) representative images of whole-cell lysine acetylation in skeletal muscle of WT, mHZ, and mKO mice. All values were normalized to the actin band on the ponceau except for total lysine-acetylation, which was normalized to whole ponceau, and all values are presented relative to WT. Data represent n = 3--6/genotype. Data presented as mean ± SEM. \*Significantly different to WT; p \< 0.05, ^\#^Significantly different to mHZ; p \< 0.05.Figure 1

2.2. Tissue collection {#sec2.2}
----------------------

Tissues were excised from fasted (4 h) and anesthetized mice. Skeletal muscles (gastrocnemius \[GA\], quadriceps \[Q\], triceps \[TRI\], tibialis anterior \[TA\], plantaris \[Pln\]), heart, liver, and epididymal adipose tissue (AT) were rinsed in sterile saline, blotted dry, weighed, and frozen in liquid nitrogen. The TA that was used for sectioning was pinned on cork and frozen in liquid nitrogen-cooled isopentane. All tissues were stored at −80 °C for subsequent analysis.

2.3. RNA extraction and cDNA synthesis for the quantitation of GCN5 gene expression {#sec2.3}
-----------------------------------------------------------------------------------

RNA was extracted from the Q muscle of WT, mHZ and mKO mice using the standard TRIzol method, and cDNA synthesized, as previously described [@bib8]. The expression of GCN5 in each sample was normalized to values of the reference control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using the comparative (2^−ΔΔCT^) method and expressed relative to WT values. Primer sequences were: GCN5 forward, 5′-CAG GTC AAG GGC TAT GGC AC-3′ and reverse, 5′-GAT AGC GGC TCT TGG GCA C-3′, GAPDH forward 5′-TGGAAAGCTGTGGCGTGAT-3′ and reverse, 5′-TGCTTCACCACCTTCTTGAT-3\'.

2.4. Skeletal muscle nuclear isolation {#sec2.4}
--------------------------------------

Isolated nuclear fractions were prepared from GA muscle using a commercially available kit (78835: NE-PER; Thermo Fisher Scientific, Waltham, MA, USA) with the addition of 4.8% cOmplete Mini protease inhibitor mixture (Sigma--Aldrich, St. Louis, MO, USA), 1 μM trichostatin A, 10 mM nicotinamide, 1 mM 1,4-Dithiothreitol, 1% Phosphatase Inhibitor Cocktail 2 (Sigma--Aldrich), 1% Phosphatase Inhibitor Cocktail 3 (Sigma--Aldrich).

2.5. GCN5 acetylatransferase activity {#sec2.5}
-------------------------------------

GCN5 specific acetyltransferase activity was determined in nuclear fractions from the GA using an immunoprecipitation HAT assay kit (17--284, Merck Millipore, Billerica, MA, USA). For this, the primary antibody in the kit was replaced with a GCN5 primary antibody (607201; Biolegend, San Diego, CA, USA) and the peptide substrate was replaced with Histone HS Peptide (12--403; Merck Millipore).

2.6. Targeted array {#sec2.6}
-------------------

Total RNA was isolated from the TRI muscle using a combination of TRIzol (Thermo Fisher Scientific) and Promega ReliaPrep RNA Tissue Miniprep System (Promega, Madison, WI, USA) according to manufacturer instructions. Isolated RNA was reverse transcribed using the RT2 First Strand Kit (SABiosciences-Qiagen, Frederick, MD, USA). A 384-well custom-designed PCR array containing pre-optimized and pre-validated primers was developed in collaboration with SABiosciences. Genes representing the functional groups: electron transport chain (ETC), metabolism, mitochondrial remodeling, mitochondrial protein transport, transcription, mitochondrial transcription, DACs, KATs, angiogenesis, poly ADP ribose polymerases (PARPs), and myogenesis. The arrays also contained a replicate positive PCR control, reaction lacking reverse transcriptase, a mouse DNA positive control and a panel of housekeeping genes including GAPDH, Actb, Hsp90ab1, B2m, Tbp. PCR was performed on the Bio Rad CFX384 thermo cycler following the manufacturer\'s protocol. Expression of each gene was normalized to the respective average value of the panel of housekeeping genes using the comparative (2^−ΔΔCT^) method and expressed relative to WT.

2.7. Energy expenditure and body composition {#sec2.7}
--------------------------------------------

Body composition was measured by magnetic resonance imaging (MRI, EchoMRI, Houston, TX, USA), and energy expenditure and voluntary cage activity were assessed using the Comprehensive Lab Animals Monitoring System (CLAMS, Columbus Instruments, Columbus, OH, USA), as previously described [@bib23]. For CLAMS, measurements were made for 3 consecutive days, and the values presented are the average diurnal values from the 12 h light and dark phases recorded on day 2 and 3.

2.8. Myosin heavy chain composition {#sec2.8}
-----------------------------------

Myosin heavy chain (MHC) composition was measured in GA, Pln, and Q muscle as previously described [@bib24], [@bib25].

2.9. High-resolution respirometry {#sec2.9}
---------------------------------

High-resolution respirometry was performed using an Oroboros O2K (Oroboros Instruments, Innsbruck, Austria) as previously described [@bib23], with minor adjustments. Specifically, the following substrate-uncoupler-inhibitor titration (SUIT) protocol was used: 0.4 mM malate, 0.2 mM octanoylcarnitine, 5 mM ADP, 10 μM cytochrome c, 5 mM pyruvate, 10 mM glutamate, 10 mM succinate, followed by 0.5 μM titrations carbonyl cyanide m-chloro phenyl hydrazone, 0.5 μM rotenone, and 2.5 μM antimycin A. Any samples showing a greater than 10% increase in respiratory flux after addition of cytochrome c were excluded from the study. Respiratory flux was normalized to muscle fiber weight. All reagents were obtained from Sigma--Aldrich.

2.10. Succinate dehydrogenase activity {#sec2.10}
--------------------------------------

Succinate dehydrogenase (SDH) activity was measured by incubation of muscle sections in medium consisting of: 1.5 mM nitro blue tetrazolium, 5 mM ethylenediaminetetraacetic acid, 48 mM succinic acid, 0.75 mM sodium azide, 30 mM methyl-phenylmethlyl sulfate, phosphate buffered to pH 7.6, for 10 min. SDH intensity was quantified in whole muscle sections of the TA with an average of 604 fibers per cross-section. Images were acquired on a Brightfield microscope (Leica DM6000, Leica Microsystems, Buffalo Grove, IL, USA) at a magnification of 10× using a (Leica DFC295 camera, Leica Microsystems) camera. Muscle sections were analyzed using image J software (ImageJ, National Institutes of Health, Bethesda, MD, USA) and mean grey values were subtracted from 255.

2.11. Endurance exercise training (ExT) {#sec2.11}
---------------------------------------

10-week old mice had free access to a running wheel for 20 days, as previously described [@bib8], [@bib23]. After 20 d, the running wheel was removed, and, 24 h following its removal, tissues were excised from fasted mice (4 h), as described above. Time spent running, distance run, and average speed were noted daily throughout ExT at 1300 h.

2.12. Immunoblotting {#sec2.12}
--------------------

Equivalent amounts of protein (30 ug) were separated on 7.5--12.5% gels by SDS-page as previously described [@bib26], proteins transferred to BioTrace NT nitro-cellulose membranes (Pall Life Sciences, Pensacola, FL, USA), blocked in 3% milk/TBST and incubated overnight in primary antibodies and subsequently incubated for 1 h at room temperature in relevant secondary antibodies. Chemiluminescence horseradish peroxidase reagent kit (Merck-Millipore) was used to quantify protein content following IgG binding. Images were captured with a G: Box Chemi-XR5 (Syngene (A Division of Synoptics Ltd.), Cambridge, UK) imaging system while blot bands were quantified using GeneTools software (Syngene).

2.13. Antibodies {#sec2.13}
----------------

All primary antibodies were used at a concentration of 1:1000 dilution unless otherwise stated. Antibodies for SIRT1 (3931), CREB-binding protein (CBP, 7389; 1:500), GAPDH (2118) hexokinase 2 (HKII, 2867), pyruvate dehydrogenase (PDH, 2784), SIRT3 (5490) p300/CBP-associated factor (PCAF, 3378), and GCN5 (3305; 1:500) were from Cell Signaling Technologies; mitochondrial-specific transcription factor A (Tfam, SAB1401383), complex I--V (OXPHOS, Ab MS664/62830) and acetyl-lysine (ab193) were from Abcam (Cambridge, UK); cytochrome-c (cyt-c, BD556433) was from BD Biosciences (Oxford, UK), long chain acyl CoA dehydrogenase (LCAD, 1:5000), and medium-chain acyl-CoA dehydrogenase (MCAD, 1:5000) were kind gifts from Prof Jerry Vockley, University of Pittsburgh, USA. PGC-1α (AB3242) was from Merck-Millipore; myogenic factor 6 (Myf6, sc-301, 1:750) and myocyte enhance factor 2 (pan-Mef2, sc-313, 1:10000) were from Santa Cruz Biotechnology, Dallas, TX, USA. Myogenic factor 4 (myogenin) F5D was deposited to the Developmental Studies Hybridoma Bank by Woodring E. Wright, University of Southwestern Medical Center, Dallas, TX, USA. Secondary antibodies were used at a concentration of 1:10000 in TBST. Anti-rabbit (7074) and anti-mouse (7076) antibodies were from Cell Signaling Technologies.

2.14. Statistical analysis {#sec2.14}
--------------------------

Statistical analyses were performed using Prism 6 (GraphPad Software Incorporated, La Jolla, CA, USA). Unpaired t-test, one-way analysis of variance (ANOVA) or two-way ANOVA, where appropriate, with Holm-Bonferroni correction for multiple comparisons was used to determine differences between WT, heterozygous (mHZ) and mKO mice. Values are presented as mean ± SEM and are expressed relative to the WT group unless otherwise stated. Statistical significance was set at p \< 0.05.

3. Results {#sec3}
==========

3.1. Generation and validation of the GCN5 mKO mouse model {#sec3.1}
----------------------------------------------------------

Skeletal muscle gene expression of GCN5 was ∼40 and ∼85% lower in mHZ and mKO mice, respectively, as compared to WT mice ([Figure 1](#fig1){ref-type="fig"}B). Following this, GCN5 protein abundance was ∼30% and 75% lower in mHZ and mKO, respectively, vs. WT mice ([Figure 1](#fig1){ref-type="fig"}C). In line with the gene and protein expression data, GCN5 acetyltransferase activity was absent in mKO vs. WT mice ([Figure 1](#fig1){ref-type="fig"}E). Notably, there was no compensatory increase in PCAF (also known as KAT2B), which is highly homologous to GCN5 [@bib27], [@bib28], [@bib29], [@bib30], at the protein ([Figure 1](#fig1){ref-type="fig"}F, G) or gene level ([Figure 2](#fig2){ref-type="fig"}G). Further, there was no up regulation of other KAT family members CBP or E1a-binding protein (p300), down-regulation of sirtuin 1 gene expression ([Figure 2](#fig2){ref-type="fig"}H), or alterations in CBP, SIRT1 or SIRT3 ([Figure 1](#fig1){ref-type="fig"}F, G) protein abundance, or alterations in whole cell lysine acetylation in mHZ or mKO compared with WT controls ([Figure 1](#fig1){ref-type="fig"}H, I).Figure 2**Targeted array reveals minimal differences in skeletal muscle gene expression between WT and GCN5 mKO**. A--K) Basal gene expression in WT and mKO TRI muscle. Heat maps represent individual fold-change in gene expression from average WT in WT and mKO mice. Data are organized into functional groups: A) electron transport chain, B) metabolism, C) mitochondrial remodeling, D) mitochondrial protein transport, E) transcription, F) mitochondrial transcription, G) acetyltransferases, H) deacetylases, I) poly ADP ribose polymerases, J) angiogenesis, K) myogenesis. Data represent individual fold change from average WT, n = 4/genotype.Figure 2

3.2. Skeletal muscle gene expression of metabolic, angiogenic, and mitochondrial genes is not affected by loss of GCN5 {#sec3.2}
----------------------------------------------------------------------------------------------------------------------

Targeted gene arrays for a wide variety of targets from the functional groups: ETC, metabolism, mitochondrial remodeling, mitochondrial protein transport, transcription, mitochondrial transcription, DACs, KATs, angiogenesis, PARPs, and myogenesis revealed no differences between mKO and WT mice (p \> 0.05; [Figure 2](#fig2){ref-type="fig"}A--K).

3.3. Body mass, composition, tissue weights, and energy expenditure are comparable between WT, mHZ, and mKO mice {#sec3.3}
----------------------------------------------------------------------------------------------------------------

There were no differences in body mass or body fat between WT, mHZ, and mKO mice ([Figure 3](#fig3){ref-type="fig"}A). Lean mass was higher in mHZ compared to WT and mKO mice (p \< 0.05). Heart, liver, and epididymal fat pad weights did not differ between genotypes in the basal state ([Table 1](#tbl1){ref-type="table"}), nor did whole-body diurnal rhythms in VO~2~, respiratory quotient (RQ), or total activity (i.e., all x axis beam breaks) differ between WT and mKO ([Figure 3](#fig3){ref-type="fig"}B--D).Figure 3**Loss of GCN5 does not alter body composition, *in vivo* metabolism or energy expenditure.** A) Body mass (BM), lean mass (LM), and fat mass (FM) determined by MRI for WT, mHZ, and mKO mice. B-D) *In vivo* measurements were made using the Comprehensive Lab Animals Monitoring System over 3 consecutive days. Data represent averages for the light and dark phases of day 2 and 3 for WT and mKO mice. B) VO~2~ and C) respiratory quotient (RQ) were measured by indirect calorimetry, while D) total activity was measured as all x-axis beam breaks. Data represent n = 5--12/genotype. Data presented as mean ± SEM. \*Significantly different to light phase; p \< 0.05, ^\#^Significantly different to WT and mKO; p \< 0.05.Figure 3Table 1Body and tissue weights in sedentary and ExT mice.Table 1SEDExT**WTmHZmKOWTmHZmKO**BW (g)25.1 ± 1.025.3 ± 1.023.3 ± 0.521.3 ± 1.7[a](#tbl1fna){ref-type="table-fn"}24.0 ± 0.6[a](#tbl1fna){ref-type="table-fn"}22.4 ± 0.6[a](#tbl1fna){ref-type="table-fn"}TA (mg)42.4 ± 1.940.6 ± 1.539.1 ± 1.039.1 ± 1.039.6 ± 1.640.8 ± 1.0% BW1.69 ± 0.041.60 ± 0.051.68 ± 0.042.77 ± 1.051.68 ± 0.081.82 ± 0.03GA (mg)110.6 ± 5.8108.4 ± 5.194.8 ± 3.199.0 ± 2.7106.1 ± 4.395.7 ± 3.7% BW4.39 ± 0.134.27 ± 0.114.07 ± 0.136.98 ± 2.654.45 ± 0.224.26 ± .10Q (mg)168.2 ± 9.5164.8 ± 8.4156.0 ± 3.6148.6 ± 2.7157.1 ± 8.8159.4 ± 4.7% BW6.67 ± 0.236.48 ± 0.176.70 ± 0.1611.30 ± 4.906.55 ± 0.347.1 ± 0.19Heart (mg)117.7 ± 5.8112.1 ± 5.6100.6 ± 3.1125.3 ± 2.6123.8 ± 3.2118.5 ± 4.1% BW4.70 ± 0.194.39 ± 0.144.32 ± 0.139.23 ± 3.785.17 ± 0.145.29 ± 0.14Liver (mg)1166.6 ± 39.41112.4 ± 46.51036.6 ± 29.21212.4 ± 37.71320.8 ± 57.61228.3 ± 62.9% BW46.55 ± 0.7043.84 ± 0.8844.26 ± 1.0948.54 ± 4.63[a](#tbl1fna){ref-type="table-fn"}55.02 ± 1.81[a](#tbl1fna){ref-type="table-fn"}52.98 ± 1.50[a](#tbl1fna){ref-type="table-fn"}Epi fat (mg)293.3 ± 22.1348.9 ± 35.7334.1 ± 35.8158.2 ± 10.6184.8 ± 17.7164.8 ± 24.2% BW11.59 ± 0.6313.54 ± 1.0914.25 ± 1.346.82 ± 0.40[a](#tbl1fna){ref-type="table-fn"}7.68 ± 0.64[a](#tbl1fna){ref-type="table-fn"}7.03 ± 0.87[a](#tbl1fna){ref-type="table-fn"}[^1]

3.4. Loss of GCN5 does not affect myosin heavy chain (MHC) composition {#sec3.4}
----------------------------------------------------------------------

Type I, IIa, IIx, and IIb MHC composition in the GA, Pln, and Q was comparable between WT and mKO ([Figure 4](#fig4){ref-type="fig"}A, B).Figure 4**Loss of GCN5 does not affect skeletal muscle MHC isoform composition.** A, B) Skeletal muscle Type IIb, IIx, IIa, and I MHC isoform composition were not different between mKO versus WT mice. A) Quantitation of MHC isoform in the gastrocnemius (GA), quadriceps (Q), and plantaris (Pln) of WT and mKO mice. B) Representative silver stain image for MHC expression in skeletal muscle of WT and mKO mice. C) Quantitation of muscle regulatory factors, Myf6, Mef2, and myogenin, protein abundance in GA whole-cell muscle lysates. D) Representative images of protein abundance of muscle regulatory factors. Values are normalized to the actin band on the ponceau and presented relative to WT. Data represent n = 5--8/genotype. Data presented as mean ± SEM.Figure 4

3.5. Markers of skeletal muscle development are unaffected by loss of GCN5 {#sec3.5}
--------------------------------------------------------------------------

Myf6, Mef2, and myogenin protein abundance did not differ between mKO, mHZ, and WT mice ([Figure 4](#fig4){ref-type="fig"}C, D). Further, MyoD gene expression was not different between mKO and WT mice ([Figure 2](#fig2){ref-type="fig"}K).

3.6. Skeletal muscle maximal respiratory capacity and succinate dehydrogenase (SDH) enzyme activity are not affected by loss of GCN5 {#sec3.6}
------------------------------------------------------------------------------------------------------------------------------------

As determined in permeabilized TA fiber bundles using high-resolution respirometry, there were no differences in maximal respiratory capacity, ETC capacity, leak respiration (in the absence of adenylates), residual oxygen consumption, and oxidative phosphorylation-coupling efficiency between WT and mKO mice ([Figure 5](#fig5){ref-type="fig"}A). Further, there were no differences in SDH activity in the TA of WT vs. mKO mice ([Figure 5](#fig5){ref-type="fig"}B, C).Figure 5**High-resolution respirometry and SDH activity in WT and mKO TA muscle.** A) Respiratory flux normalized to muscle fiber weight in the presence of MOct (leak respiration in the absence of adenylates), ADP (D), cytochrome c (C; mitochondrial integrity), pyruvate (P), glutamate (G; complex I (CI) capacity), succinate (S; complex I + complex II (CII) capacity), carbonyl cyanide m-chloro phenyl hydrazone (U; maximal respiration), rotenone (Rot; complex II capacity), and Ama (residual oxygen consumption (Rox)). B) Quantitation (data presented relative to WT) and C) representative images of SDH activity in WT and mKO TA muscle. Data represent n = 5--7/genotype. Data presented as mean ± SEM.Figure 5

3.7. Loss of GCN5 does not affect mitochondrial content or adaptations to ExT {#sec3.7}
-----------------------------------------------------------------------------

Average 24 h running distance and running speed were comparable between genotypes ([Figure 6](#fig6){ref-type="fig"}A, B); as expected, daily distance and average speed increased over the first 10 d of training (p \< 0.05). Although skeletal muscle weights were similar between sedentary (SED) and ExT groups, epididymal fat weight was lower and liver weight higher (p \< 0.05) following ExT, with no genotype differences observed ([Table 1](#tbl1){ref-type="table"}). At the molecular level, ExT increased the skeletal muscle abundance of mitochondrial markers (∼1.3--2.5 fold), including complexes I-V, cyt-c, MCAD, LCAD, HKII, PDH, PGC-1α and SIRT3, as compared to SED (p \< 0.05; [Figure 6](#fig6){ref-type="fig"}C--F); there were no genotype differences within SED or ExT groups (p \> 0.05).Figure 6**Loss of GCN5 in skeletal muscle does not inhibit the ability for exercise training or exercise-induced mitochondrial adaptation** A) Average 24 h running distance and B) average 24 h running speed during 20 days ExT in WT, mHZ, and mKO. C, D) (C) Quantitation (D) and representative images of protein abundance of electron transport chain complexes (complex I (CI), complex II (CII), complex III (CIII), complex IV (CIV), and complex V (CV)) and cytochrome-c (cyt-c) in TRI muscle from SED and ExT WT, mHZ, and mKO mice. E, F) (E) Quantitation (F) and representative images of protein abundance of MCAD, LCAD, HKII, PDH, PGC-1α, and TFAM in TRI muscle from SED and ExT WT and mKO mice. All values were normalized to the actin band on the ponceau and all values are presented relative to WT-SED. (Data represent n = 5--9/genotype). Data presented as mean ± SEM. \*Significant effect for exercise; p \< 0.05.Figure 6

4. Discussion {#sec4}
=============

The role of reversible lysine acetylation in skeletal muscle metabolism has received considerable interest in recent years [@bib7], [@bib8], [@bib13], [@bib17], [@bib31], [@bib32]. To date, the contribution of DACs, particularly SIRT1 and SIRT3, to the positive metabolic adaptations in skeletal muscle to exercise training have been heavily studied [@bib6], [@bib7], [@bib8], [@bib31]. In contrast, very little is known about the contribution of KATs to skeletal muscle metabolism and remodeling *in vivo*. To address this, we developed a conditional mouse model in which GCN5 activity is deleted in muscle. The primary reason for focusing on GCN5 is that previous *in vitro* studies have demonstrated its key role in acetylating and inhibiting PGC-1α, thereby opposing the actions of SIRT1 [@bib17], [@bib18], [@bib21]. Our results reveal that whole-body energy expenditure, skeletal muscle morphology, mitochondrial protein abundance, and maximal respiratory capacity are comparable between sedentary mKO, mHZ, and WT mice, as is the induction of skeletal muscle mitochondrial biogenesis in response to endurance exercise training.

Reversible acetylation is a major mechanism by which the transcriptional activity of PGC-1α is regulated [@bib16], [@bib20], [@bib21], [@bib33], [@bib34]. In elegant cell-based studies, a role for SIRT1 in modulating the transcriptional capacity of PGC-1α via its deacetylation has been well documented [@bib6], [@bib17], [@bib20], [@bib34], while its role *in vivo* remains controversial [@bib6], [@bib8], [@bib16], [@bib31], [@bib35], [@bib36]. In fact, studies in bona fide skeletal muscle provide little support for a direct role of SIRT1 in modulating skeletal muscle mitochondrial biogenesis [@bib8], [@bib31]. In contrast, GCN5 acetylates PGC-1α *in vitro* and inhibits its transcriptional activity [@bib8], [@bib17], [@bib18], [@bib21], with overexpression of GCN5 in C2C12 myotubes leading to repression of PGC-1*α*-mediated induction of mitochondrial and fatty acid metabolism genes [@bib17]. Moreover, in Fao hepatocytes [@bib17] and skeletal muscle [@bib8] GCN5 and PGC-1α coimmunoprecipitate, while GCN5 overexpression in HEK293 cells represses PGC-1α intrinsic transcriptional activity [@bib18]. The repressive effects of GCN5-mediated acetylation on PGC-1α appear to be due to altered cellular distribution of PGC-1α, with hyperacetylation segregating PGC-1α from target promoters and towards nuclear foci [@bib18]. With these findings in mind, we expected that mitochondrial function and abundance, whole body energy expenditure, and exercise training-induced mitochondrial adaptations would be enhanced in our mKO mouse. To our surprise, however, neither partial (i.e. mHZ) nor complete (i.e. mKO) loss of GCN5 altered any of these parameters.

A potential explanation for the lack of effect of the loss of GCN5 on skeletal muscle metabolic or mitochondrial remodeling may be due to compensation from other KATs. PCAF shares ∼73% homology with the GCN5 gene [@bib27], [@bib28], [@bib29], [@bib30], whilst GCN5 and p300 have numerous substrates in common [@bib37]. Indeed, GCN5/PCAF whole-body double KO mice (GCN5^−/−^ PCAF^−/−^) die earlier than GCN5 whole-body KO mice, inferring shared functions between these two proteins [@bib38]. Furthermore, an often overlooked observation in the study of Lerin et al. [@bib18], which identified GCN5 as the specific acetyltransferase of PGC-1α, is the fact that PCAF induced acetylation of PGC-1α, albeit to a lesser extent than GCN5. Further, *in vitro*, PCAF-mediated acetylation of two lysine residues (K328 and K450) on PGC-1α accelerates its proteasomal degradation and suppresses the transcriptional activity of PGC-1α [@bib39]. In liver of fasted and diabetic mice, PCAF acetylated PGC-1α, while liver-specific knockdown of PCAF increased PGC-1α abundance and activity and led to an increase in hepatic glucose output [@bib39]. Notably, however, whether GCN5 and PCAF acetylate and/or recognize the same lysine residues or whether PCAF interacts with PGC-1α in skeletal muscle is unknown. Embryonic redundancy between GCN5 and p300 also exists, with mice heterozygous for null alleles of both GCN5 and p300 demonstrating reduced viability compared to mice heterozygous for either single mutation [@bib40]. Additionally, while p300 has been shown to induce acetylation of PGC-1α [@bib34], it can also prompt a conformational change that increases (not decreases) PGC-1α transcriptional activity, *in vitro* [@bib41]. Importantly, however, we recently demonstrated that loss of p300 in skeletal muscle does not impact mitochondrial function or metabolic adaptations to endurance exercise [@bib23]. In the present study, although there was no up-regulation of PCAF protein content or gene expression, or p300 gene expression in mHZ and mKO mice, redundancy or overlapping functions of GCN5 with PCAF and/or p300 could explain the lack of differences we see between mKO/mHZ and WT mice. To this end, clearly more work is required to understand the redundancy between these KAT family members in skeletal muscle *in vivo*.

GCN5 is fundamental to development, as evidenced by the embryonic lethality seen in whole body KO and whole body GCN5^hat/hat^ (embryos with mutant GCN5 KAT activity) mice [@bib38], [@bib42]. In these mice, severe retardation is evident by 8.5 days post coitum (dpc) and death at 10.5 and 16.5 dpc in the KO and KO^hat/hat^, respectively [@bib38], [@bib42]. This retardation is characterized, in part, by the failure to form the paraxial mesoderm and somites [@bib38], [@bib42], which go on to form skeletal muscle [@bib43]. As GCN5 whole body KO embryos are not viable beyond ∼10 dpc, a point in development in which early myogenic regulatory genes are beginning to be expressed [@bib44], [@bib45], [@bib46], the contribution of GCN5 to skeletal muscle development is currently unknown. Nonetheless, as embryonic lethality coincides with failure to form somites, there is reason to consider that GCN5 may be important for development of myogenic precursor cells. Also, acetylation of MyoD, one of the earliest markers of myogenic commitment, by PCAF and/or p300 is considered critical for execution of the skeletal muscle program [@bib46], [@bib47], [@bib48], and suggests that lysine acetylation has a role in skeletal muscle development. In our mKO model, cre-mediated KO of GCN5 would occur after induction of MCK at ∼13 dpc [@bib44]. Considering mKO and mHZ mice demonstrate no overt differences in muscle weights, fiber type, or myogenic genes as compared to WT littermates, our data suggest that, in and of itself, GCN5 is not required for muscle development *in vivo*. Finally, GCN5 was originally identified as a transcriptional regulator due to its ability to acetylate histones and modify chromatin structure [@bib49] Indeed, it is now considered to be the catalytically active KAT of multiple histone acetyltansferase complexes [@bib10]. With this in mind, we expected to see differences in skeletal muscle gene expression between our WT and mKO mice. Somewhat surprisingly, however, we found no influence of the loss of GCN5 on the expression of ∼50 different genes indicative of a wide variety of functions in skeletal muscle. These findings could simply be due to the fact that GCN5 is not important for skeletal muscle development or transcriptional control, or as discussed above, could be due to redundancy and compensation from other KATs.

5. Conclusion {#sec5}
=============

While *in vitro* data provide a mechanistic link between GCN5 acetyltransferase activity and metabolism, our results suggest that loss of GCN5 in muscle does not enhance *in vivo* basal or ExT-induced metabolic adaptation. Further, we show that GCN5 is not required for adult skeletal muscle development nor does it alter myosin heavy chain composition, whole cell lysine acetylation or gene expression in skeletal muscle. Given the homology between PCAF and GCN5 [@bib27], [@bib28], [@bib29], [@bib30] and their demonstrated overlapping functions during embryogenesis [@bib38], as well as commonality in substrates between p300 and GCN5 [@bib37], it will be of high interest in future studies to probe the separate and combined effects of GCN5, p300 and/or PCAF on skeletal muscle biology.
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[^1]: Main effect for effect for exercise training (ExT); p \< 0.05. SED, sedentary; ExT, endurance exercise training; BW, body weight; TA, tibialis anterior; GA, gastrocnemius; Q, quadriceps, Epi fat; epididymal fat.
